| Patents for A61P 37 - Drugs for immunological or allergic disorders (117,141) |
|---|
| 06/15/2004 | US6750034 Useful as therapeutic agents for cancer, skin disorders, neuropathic pain, inflammatory, or coagulation diathesis/thrombosis; may also be useful for laundry detergents and skin care products; derived from humans |
| 06/15/2004 | US6749854 Use of OX-2 to inhibit fetal loss |
| 06/15/2004 | CA2159330C Inhibition of leukocyte adhesion |
| 06/15/2004 | CA2049921C Allergenic proteins from ragweed and uses therefor |
| 06/13/2004 | CA2451267A1 Pharmaceutical uses for alpha2delta ligands |
| 06/10/2004 | WO2004048974A1 Functional domain and associated molecule of dock2 essentially required in lymphocyte migration |
| 06/10/2004 | WO2004048574A1 Immunoreceptor proteins |
| 06/10/2004 | WO2004048565A1 Apoptosis-associated protein and use thereof |
| 06/10/2004 | WO2004048512A2 Novel proteins and nucleic acids encoding same |
| 06/10/2004 | WO2004048497A1 External composition containing highly unsaturated fatty acid or its salt or ester |
| 06/10/2004 | WO2004048496A1 Composition containing organic substance having double bond with improved oxidation stability |
| 06/10/2004 | WO2004048411A2 Compounds and methods for modulating desmosomal and atypical cadherin-mediated cell adhesion |
| 06/10/2004 | WO2004048410A2 T-cell receptors |
| 06/10/2004 | WO2004048378A1 Pyrazoloquinolines with immunomodulating activity |
| 06/10/2004 | WO2004048322A1 Cannabinoid receptor ligands |
| 06/10/2004 | WO2004048287A1 Hardening bone compensate and remedy for skin defect using calcium phosphate sustainedly releasing zinc |
| 06/10/2004 | WO2004047850A1 Papaya puree and the use of the same |
| 06/10/2004 | WO2004047848A1 New use of dextran sulfate |
| 06/10/2004 | WO2004047846A1 Oil/glycyrrhizin-containing surfactant phase type gel composition |
| 06/10/2004 | WO2004047842A1 Treatment of immune system dysfunction |
| 06/10/2004 | WO2004047826A1 Combination of diamide derivatives and immunosuppressive agents for induction of immune tolerance |
| 06/10/2004 | WO2004047818A2 USE OF TFG-β INHIBITORSTO COUNTERACT PATHOLOGIC CHANGES IN THE LEVEL OR FUNCTION OF STEROID/THYROID RECEPTORS |
| 06/10/2004 | WO2004047812A1 Hollow nanoparticles of protein and drug using the same |
| 06/10/2004 | WO2004047728A2 Compositions and methods for the treatment of immune related diseases |
| 06/10/2004 | WO2004047725A2 8-hydroxy-1-oxo-tetrahydropyrrolopyrazine compounds useful as hiv integrase inhibitors |
| 06/10/2004 | WO2004017810A3 Tumor specific oligosaccharide epitopes and use thereof |
| 06/10/2004 | WO2004006950A3 Use of cd152 for treating autoimmune diseases and inflammations |
| 06/10/2004 | WO2004004698A3 Proteins binding to cross-beta structure comprising amyloid and methods for detection and modulation of the cross-beta structure, its formation and its associated toxicity |
| 06/10/2004 | WO2004004633A3 Use of tnfalpha antibodies and another drug |
| 06/10/2004 | WO2004003235A3 Probiotic strains, a process for the selection of them, compositions thereof, and their use |
| 06/10/2004 | WO2003089571A3 Ehrlichia canis genes and vaccines |
| 06/10/2004 | WO2003084943A9 Terphenyl derivatives, preparation thereof, compositions containing same |
| 06/10/2004 | WO2003083039A8 Therapeutic polypeptides, nucleic acids encoding same, and methods of use |
| 06/10/2004 | WO2003072027A3 Compositions and formulations of 9- nitrocamptothecin polymorphs and methods of use thereof |
| 06/10/2004 | WO2003070970A3 RNA INTERFERENCE MEDIATED INHIBITION OF NF-KAPPA B/REL-A GENE EXPRESSION USING SHORT INTERFEREING NUCLEIC ACID (siNA) |
| 06/10/2004 | WO2003064626A3 Double-stranded oligonucleotides |
| 06/10/2004 | WO2003015711A3 Combination motif immune stimulatory oligonucleotides with improved activity |
| 06/10/2004 | WO2003013603A8 Modulators of p-selectin glycoprotein ligand 1 |
| 06/10/2004 | US20040110956 Novel aminoindazole derivatives as medicaments and pharmaceutical compositions including them |
| 06/10/2004 | US20040110952 e.g., N-[1-(3-phenyl-3-[cyclopenytlacetylamino]propyl)-4-piperidinyl]-N-ethyl-4-methanesulfonylphenylacetamide |
| 06/10/2004 | US20040110945 Very Late Antigen (Vla-4); such as 4-((4S)-fluoro-1-(2-phenylamino-6-benzoxazolylacetyl)-(2S)-pyrrolidinylmethoxy)benzoic acid; for treatment of inflammatory diseases, autoimmune diseases, metastasis, bronchial asthma, rhinostenosis, and diabetes |
| 06/10/2004 | US20040110928 Peptide conjugates for drug delivery |
| 06/10/2004 | US20040110846 Perylenequinones for use with immunotherapy agents |
| 06/10/2004 | US20040110832 management, treatment and/or control of diseases caused in intrinsic clotting pathway utilizing factor IX such as stroke, myocardial infarction, aneurysm surgery, and deep vein thrombosis associated with surgical procedures etc |
| 06/10/2004 | US20040110810 e.g., 2-(2-methyl-5-amino)phenyl-4-(3-pyridyl)-thiazole; c-kit inhibitors; treating cell proliferative, metabolic, allergic, and degenerative disorders. |
| 06/10/2004 | US20040110809 di- and tricycle-substituted imidazolidine-, oxazolidine- and thiazolidine diones and thiones, e.g., 5-[p-(quinolin-3-yl)-alpha-hydroxybenzyl]-5-methylimidazolidinedione |
| 06/10/2004 | US20040110805 Sulfur compounds such as 4-[(4-{3-[(2-adamantylamino)sulfonyl]propoxy}phenyl)sulfonyl]- N-hydroxytetrahydro-2H-pyran-4-carboximide, used as antagonists for metalloenzyme and/or aggrecanase activity; tissue repair |
| 06/10/2004 | US20040110801 Prevention of degenerative joint diseases, rheumatoid arthritis, osteoarthritis, ulcerative colitis, irritable colon and Crohn's diseas, antitumor agents; drug mixture for transdermal drug delivery, sustained release; chemical synthesis |
| 06/10/2004 | US20040110794 Novel piperidine derivatives as modulators of chemokine receptors |
| 06/10/2004 | US20040110793 Heterocyclo inhibitors of potassium channel function |
| 06/10/2004 | US20040110779 Hydantoin derivsatives with affinity for somatostatin receptors |
| 06/10/2004 | US20040110774 HIV infection, AIDS, and adenosine deaminase deficiency-dependent severe immunodeficiency disease (ADA SCID); antagonists are antibodies |
| 06/10/2004 | US20040110763 Pyrazolopyridine compound and pharmaceutical use thereof |
| 06/10/2004 | US20040110759 Inhibitors of IkB kinase (I Kappa B Kinase); treating various diseases including asthma, osteoarthritis, rheumatoid arthritis, Alzheimer's disease, cancer, infections, and cardiac infarct |
| 06/10/2004 | US20040110753 Tyrosine derivatives |
| 06/10/2004 | US20040110752 2-amino-5-((hetero)aryl)-thiazole derivatives; treatment of disorders such as cancer, immunologic disorders and allergic disorders, optionally in combination with other drugs such as immunosuppressants |
| 06/10/2004 | US20040110746 Piperazinyl and diazapanyl benzamides and benzthioamides |
| 06/10/2004 | US20040110736 Cyclic derivatives as modulators of chemokine receptor activity |
| 06/10/2004 | US20040110734 Combinations for the treatment of inflammatory disorders |
| 06/10/2004 | US20040110728 Agonists and antagonists of sphingosine-1-phosphate receptors |
| 06/10/2004 | US20040110718 Anti-HCV nucleoside derivatives |
| 06/10/2004 | US20040110715 Differs from nucleotide sequence of wild-type IFN alpha -17 gene, in that it comprises one or several SNPs (Single Nucleotide Polymorphism[s]); anticarcinogenic and antiproliferative agents; side effect reduction |
| 06/10/2004 | US20040110704 Decreased or deleted activity of enzyme with modified sugar chain in which 1-position of fucose is bound to 6-position of N-acetylglucosamine in reducing end; antitumor agents, cardiovascular disorders, autoimmune diseases |
| 06/10/2004 | US20040110695 Phospholipid vesicle having exogenous antigen orpolynucleic acid coding for antigen; adapted to be phagocytosed by antigen presenting cells |
| 06/10/2004 | US20040110282 Cells in which activity of the protein involved in transportation of GDP-fucose is reduced or lost |
| 06/10/2004 | US20040110270 Bacterial composition and its use |
| 06/10/2004 | US20040110263 Glycosylphosphatidylinositol specific phospholipase d proteins for the treatment or diagnosis of atherosclerosis |
| 06/10/2004 | US20040110237 Protein localization assays for toxicity and antidotes thereto |
| 06/10/2004 | US20040110236 comprises administering the hepatocytes or plasma cells or T cells to an animal after stimulation in vitro |
| 06/10/2004 | US20040110218 BMOG, a novel protein member of the myelin-oligodendrocyte glycoprotein family and its use for immunomodulatory purposes |
| 06/10/2004 | US20040110181 Novel streptococcus pneumoniae open reading frames encoding polypeptide antigens and uses thereof |
| 06/10/2004 | US20040110180 Comprises enzymatic polypeptide for diagnosis, treatment and prevention of cardiovascular, immune system, nervous system, lipid and cell proliferative disorders; drug screening |
| 06/10/2004 | US20040109878 Removal cancer, organ transplant and autoimmune cells from bone marrow, blood |
| 06/10/2004 | US20040109877 Rna viruses; attenuation influenza virus |
| 06/10/2004 | US20040109866 Immonotherapy complex containing antigen, antibodies, epitopes; binding to receptors |
| 06/10/2004 | US20040109865 Antibody composition-containing medicament |
| 06/10/2004 | US20040109859 Method for the treatment of multiple sclerosis |
| 06/10/2004 | US20040109857 Methods of therapy for b-cell malignancies using antagonist anti-cd40 antibodies |
| 06/10/2004 | US20040109847 Treatment and prophylaxis with 4-1BB-binding agents |
| 06/10/2004 | CA2854831A1 Treatment of mammalian reaction to ige interactions |
| 06/10/2004 | CA2506895A1 Cannabinoid receptor ligands |
| 06/10/2004 | CA2506611A1 External composition containing polyunsaturated fatty acid or its salt or ester |
| 06/10/2004 | CA2506524A1 Pyrazoloquinolines with immunomodulating activity |
| 06/10/2004 | CA2506037A1 Compounds and methods for modulating desmosomal and atypical cadherin-mediated cell adhesion |
| 06/10/2004 | CA2504144A1 Compositions and methods for the diagnosis of immune related diseases using pro7 |
| 06/10/2004 | CA2498566A1 8-hydroxy-1-oxo-tetrahydropyrrolopyrazine compounds useful as hiv integrase inhibitors |
| 06/09/2004 | EP1426060A1 Remedies for allergic diseases |
| 06/09/2004 | EP1426052A1 Compositions comprising interleukin-2 and gamma-delta T cell activator and uses thereof |
| 06/09/2004 | EP1426050A1 Jnk inhibitors |
| 06/09/2004 | EP1425409A2 Hybrid interferon/interferon tau proteins, compositions and methods of use |
| 06/09/2004 | EP1425408A2 Chemo-enzymatic synthesis of sialylated oligosaccharides |
| 06/09/2004 | EP1425396A2 Dna encoding the major allergen of plantago lanceolata pollen, pla 11 |
| 06/09/2004 | EP1425389A2 Human antibodies specific for interleukin 15 (il-15) |
| 06/09/2004 | EP1425388A2 A method for isolating, culturing and differentiating intestinal stem cells for therapeutic use |
| 06/09/2004 | EP1425308A2 Polysaccharidic esters of retinoic acid |
| 06/09/2004 | EP1425306A2 Nanoparticles comprising biologically active tnf which is immobilised on the same |
| 06/09/2004 | EP1425305A1 Igf-1 as feline vaccine adjuvant, in particular against feline retroviruses |
| 06/09/2004 | EP1425303A2 Use of proteins for the production of a medicament for stimulating the innate non specific immune system |
| 06/09/2004 | EP1425301A2 Therapeutic vaccine peptide complex for preventing and treating disorders in mammals |
| 06/09/2004 | EP1425299A2 Peptides derived from the superantigen (sag) env protein of herv-k18 and their use in obtaining sag-inhibitory antibodies and in vaccination |